Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Asahi Kasei Pharma to Start Clinical Trials in 2012 of US Transdermal Patch Formulation
October 12, 2011
- NanoCarrier, France’s LFB Agree on Joint Research Agreement
October 12, 2011
- MediciNova Gets Approval for Chinese Joint Venture
October 12, 2011
- PIII Study of Rivaroxaban in Patients with ACS to be Presented at AHA Congress: Bayer
October 12, 2011
- Takeda Bio Initiates P1/2 Trial of Malignant Lymphoma Treatment in Japan
October 12, 2011
- AZ to Invest $200 Mil. to Build New Factory in China
October 12, 2011
- Merck Receives FDA Approval for Fixed Dose Combination of Januvia, Simvastatin
October 12, 2011
- PACIFIC Study Finds Higher Rate of STEMI in ACS in Japanese
October 12, 2011
- Takeda Discontinues Development of Insomnia Drug Ramelteon in Europe
October 11, 2011
- Sales of Publicly Funded Vaccines Continue to Increase in August: Crecon Research & Consulting
October 11, 2011
- AZ to Reduce US HQ Staff by approx. 400
October 11, 2011
- Anti-emetic Proemend IV Infusion 150 mg Approved: Ono
October 10, 2011
- Ilaris Approved as Japan’s 1st CAPS Treatment: Novartis Pharma
October 10, 2011
- Teribone Approved for Osteoporosis with High Fracture Risk: Asahi Kasei Pharma
October 10, 2011
- TachoSil Tissue Sealing Sheet Approved: CSL Behring
October 10, 2011
- Avastin Receives Add’l Indication for Breast Cancer: Chugai
October 10, 2011
- Onyx Submits NDA in US for Carfilzomib in MM: Ono
October 10, 2011
- Eisai, Abbott Japan File for Additional Indication for Humira
October 10, 2011
- CHMP Issues Positive Opinion on New ARB Edarbi: Takeda
October 10, 2011
- Cubicin 350 mg IV Inj. Launched for MRSA Infections: MSD
October 10, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…